Eyenovia, INC Form 4 insider transactions

Tsontcho Ianchulev, a director at Eyenovia, files an amended Form 4 to correct a clerical error regarding the amount of securities beneficially owned directly, following a reverse stock split and ahead of a proposed business combination with Betaliq, Inc.

Michael Geltzeiler, a director at Eyenovia, Inc., files an amended Form 4/A to correct a clerical error in the originally reported amount of securities beneficially owned, following a reverse stock split and ahead of a proposed business combination with Betaliq, Inc.

Director Ellen Strahlman reports acquisition of Eyenovia shares, including restricted stock units contingent on the company's merger with Betaliq, Inc.

Director Ram Palanki acquired 3,000 restricted stock units in Eyenovia, Inc., contingent on the closing of the proposed business combination with Betaliq, Inc.

Charles E. Mather IV, a director of Eyenovia, Inc., acquired 8,000 shares of common stock upon the closing of the company's business combination with Betaliq, Inc.

Chief Operating Officer of Eyenovia, Bren Kern, reports acquiring 50,000 shares of common stock on April 21, 2025.

Director Rachel Jacobson reports acquiring 3,000 shares of Eyenovia, Inc. common stock related to restricted stock units vesting upon the closing of the proposed business combination with Betaliq, Inc.

Director Tsontcho Ianchulev reports acquiring 5,000 shares of Eyenovia stock, with vesting contingent on the closing of the proposed business combination with Betaliq, Inc.

Michael Geltzeiler, a director of Eyenovia, Inc., acquired 5,000 restricted stock units contingent upon the closing of the company's merger with Betaliq, Inc.

Andrew D. Jones, CFO of Eyenovia, Inc., was granted stock options to purchase 200,000 shares of common stock.

Eyenovia's CEO, Michael Rowe, acquired 27,071 shares of common stock at $0.52 per share on August 28, 2024, increasing his direct holdings.

Eyenovia's CEO, Michael Rowe, recently purchased 50,000 shares of the company's common stock at a price of $0.57 per share.

Stuart M. Grant, a significant shareholder of Eyenovia, Inc., acquired additional common stock and warrants, increasing his beneficial ownership in the company.

Director Ellen R. Strahlman reports acquisition of common stock and stock options in Eyenovia, Inc.

Director Ram Palanki reports acquisition of common stock and stock options in Eyenovia, Inc.

Director Charles E. Mather IV reports acquisition of restricted stock units and stock options in Eyenovia, Inc.

Director Rachel Jacobson reports acquisition of restricted stock units and stock options in Eyenovia, Inc.

Director Tsontcho Ianchulev reports acquisition of stock options and restricted stock units in Eyenovia, along with the disposal of some common stock.

Director Michael Geltzeiler reports acquisition of Eyenovia shares and stock options, along with disposal of shares.

Director Stuart M. Grant reports purchasing 100,000 shares of Eyenovia, Inc. at $0.98 per share.

Stuart M. Grant, a director of Eyenovia, Inc., purchased 50,000 shares of common stock at an average price of $1.23 per share on March 19, 2024.

Stuart M. Grant, a director of Eyenovia, Inc., purchased 10,717 shares of common stock on March 8, 2024.